Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of ophthalmology 2007-09, Vol.91 (9), p.1244-1246
Hauptverfasser:	Raftery, James, Clegg, Andrew, Jones, Jeremy, Tan, Seng Chuen, Lotery, Andrew
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Biological and medical sciences Cost-Benefit Analysis Drug Costs - statistics & numerical data Humans Macular degeneration Macular Degeneration - drug therapy Macular Degeneration - economics Macular Degeneration - physiopathology Markov Chains Medical sciences Miscellaneous Models, Econometric Ophthalmology Quality-Adjusted Life Years Ranibizumab Treatment Outcome Visual Acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!